BioArctic: Interim Report for the period April - June 2026

EarningsLeqembiPositive

AI Analysis

Summary

BioArctic released interim report for Q2 2026 announcing new approvals for Leqembi and additional strategic partnerships, with Eisai providing a sales forecast of JPY 143.5 billion for fiscal year 2026.

Financial Highlights

Guidance

JPY 143.5 billion (Leqembi sales forecast for Eisai fiscal year April 2026 to March 2027)

Importance:4/10

Sentiment:

0.30

interim reportQ2 2026Leqembisales forecaststrategic partnerships

Related Companies

$BIOA-B.ST $ESALY

Read the original article

Published by PR Newswire Biotech on August 26, 2026 6:46 AM

Read Original